Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:3678595rdf:typepubmed:Citationlld:pubmed
pubmed-article:3678595lifeskim:mentionsumls-concept:C0008059lld:lifeskim
pubmed-article:3678595lifeskim:mentionsumls-concept:C0039771lld:lifeskim
pubmed-article:3678595lifeskim:mentionsumls-concept:C0004096lld:lifeskim
pubmed-article:3678595lifeskim:mentionsumls-concept:C0005508lld:lifeskim
pubmed-article:3678595lifeskim:mentionsumls-concept:C0030685lld:lifeskim
pubmed-article:3678595lifeskim:mentionsumls-concept:C0205345lld:lifeskim
pubmed-article:3678595lifeskim:mentionsumls-concept:C1521827lld:lifeskim
pubmed-article:3678595lifeskim:mentionsumls-concept:C0680255lld:lifeskim
pubmed-article:3678595lifeskim:mentionsumls-concept:C0391871lld:lifeskim
pubmed-article:3678595lifeskim:mentionsumls-concept:C1283071lld:lifeskim
pubmed-article:3678595lifeskim:mentionsumls-concept:C1963578lld:lifeskim
pubmed-article:3678595lifeskim:mentionsumls-concept:C0439834lld:lifeskim
pubmed-article:3678595lifeskim:mentionsumls-concept:C0205344lld:lifeskim
pubmed-article:3678595pubmed:issue5lld:pubmed
pubmed-article:3678595pubmed:dateCreated1988-1-19lld:pubmed
pubmed-article:3678595pubmed:abstractTextThis study was carried out on 14 asthmatic children aged 7-13 years. They all received three preparations (aminophylline by intravenous infusion, lysine theophyllinate orally in solution and slow release theophylline orally as capsules) in a single dose of 100 mg active ingredient in a crossover design. Plasma theophylline concentrations, determined by a fluorescent polarization immunoassay, were evaluated both by compartmental and non-compartmental analysis. After administration of slow release theophylline, its maximum plasma concentration and the time needed to reach this were (+/- SD) 3.19 +/- 0.63 microgram/ml and 8.71 +/- 2.30 h, respectively, compared to 4.51 +/- 0.94 microgram/ml and 1.96 +/- 0.85 h, respectively, for the oral normal release solution. Mean absolute and relative percentage bioavailabilities for slow release theophylline in asthmatic children were (+/- SD) 92.7 +/- 23.2% and 83.14 +/- 14.69%, respectively. These are similar to the values found with other slow release formulations in paediatric patients.lld:pubmed
pubmed-article:3678595pubmed:languageenglld:pubmed
pubmed-article:3678595pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3678595pubmed:citationSubsetIMlld:pubmed
pubmed-article:3678595pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3678595pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3678595pubmed:statusMEDLINElld:pubmed
pubmed-article:3678595pubmed:issn0300-0605lld:pubmed
pubmed-article:3678595pubmed:authorpubmed-author:PlebaniMMlld:pubmed
pubmed-article:3678595pubmed:authorpubmed-author:VenturaPPlld:pubmed
pubmed-article:3678595pubmed:authorpubmed-author:BonerA LALlld:pubmed
pubmed-article:3678595pubmed:authorpubmed-author:ValloneGGlld:pubmed
pubmed-article:3678595pubmed:authorpubmed-author:De StefanoGGlld:pubmed
pubmed-article:3678595pubmed:issnTypePrintlld:pubmed
pubmed-article:3678595pubmed:volume15lld:pubmed
pubmed-article:3678595pubmed:ownerNLMlld:pubmed
pubmed-article:3678595pubmed:authorsCompleteYlld:pubmed
pubmed-article:3678595pubmed:pagination282-92lld:pubmed
pubmed-article:3678595pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:3678595pubmed:meshHeadingpubmed-meshheading:3678595-...lld:pubmed
pubmed-article:3678595pubmed:meshHeadingpubmed-meshheading:3678595-...lld:pubmed
pubmed-article:3678595pubmed:meshHeadingpubmed-meshheading:3678595-...lld:pubmed
pubmed-article:3678595pubmed:meshHeadingpubmed-meshheading:3678595-...lld:pubmed
pubmed-article:3678595pubmed:meshHeadingpubmed-meshheading:3678595-...lld:pubmed
pubmed-article:3678595pubmed:meshHeadingpubmed-meshheading:3678595-...lld:pubmed
pubmed-article:3678595pubmed:meshHeadingpubmed-meshheading:3678595-...lld:pubmed
pubmed-article:3678595pubmed:meshHeadingpubmed-meshheading:3678595-...lld:pubmed
pubmed-article:3678595pubmed:meshHeadingpubmed-meshheading:3678595-...lld:pubmed
pubmed-article:3678595pubmed:meshHeadingpubmed-meshheading:3678595-...lld:pubmed
pubmed-article:3678595pubmed:meshHeadingpubmed-meshheading:3678595-...lld:pubmed
pubmed-article:3678595pubmed:articleTitleAbsolute and relative bioavailability of a slow release theophylline preparation in asthmatic children.lld:pubmed
pubmed-article:3678595pubmed:affiliationPaediatric Clinic, University of Verona, Italy.lld:pubmed
pubmed-article:3678595pubmed:publicationTypeJournal Articlelld:pubmed